What is CME Group's earnings per share (EPS)?

CME Group (CME) reported diluted earnings per share of $11.16 for fiscal year 2025. This represents a 15.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

CME Group Financials

CME

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows CME Group (CME) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 50/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

100

CME Group has an operating margin of 64.9%, meaning the company retains $65 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is up from 64.1% the prior year.

Growth

CME Group's revenue grew 6.4% year-over-year to $6.5B, a solid pace of expansion. This earns a growth score of 44/100.

Leverage

CME Group has elevated debt relative to equity (D/E of 5.91), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

CME Group's current ratio of 1.03 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 16/100, which could limit financial flexibility.

Cash Flow

100

CME Group converts 64.3% of revenue into free cash flow ($4.2B). This strong cash generation earns a score of 100/100.

Returns

CME Group's ROE of 14.2% shows moderate profitability relative to equity, earning a score of 43/100. This is up from 13.3% the prior year.

Altman Z-Score Distress

0.57

CME Group scores 0.57, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($110.7B) relative to total liabilities ($169.7B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Neutral

4/9

CME Group passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.05x

For every $1 of reported earnings, CME Group generates $1.05 in operating cash flow ($4.3B OCF vs $4.1B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

24.4x

CME Group earns $24.4 in operating income for every $1 of interest expense ($4.2B vs $173.4M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$6.5B

YoY+6.4%

5Y CAGR+6.0%

10Y CAGR+7.0%

CME Group generated $6.5B in revenue in fiscal year 2025. This represents an increase of 6.4% from the prior year.

EBITDA

$4.3B

YoY+7.2%

5Y CAGR+9.2%

10Y CAGR+7.4%

CME Group's EBITDA was $4.3B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.2% from the prior year.

Net Income

$4.1B

YoY+15.5%

5Y CAGR+14.1%

10Y CAGR+12.6%

CME Group reported $4.1B in net income in fiscal year 2025. This represents an increase of 15.5% from the prior year.

EPS (Diluted)

$11.16

YoY+15.4%

5Y CAGR+13.7%

10Y CAGR+11.7%

CME Group earned $11.16 per diluted share (EPS) in fiscal year 2025. This represents an increase of 15.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$4.2B

YoY+16.6%

5Y CAGR+10.7%

10Y CAGR+11.5%

CME Group generated $4.2B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 16.6% from the prior year.

Cash & Debt

$4.4B

YoY+52.7%

5Y CAGR+22.0%

10Y CAGR+10.1%

CME Group held $4.4B in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

$5.00

YoY-51.9%

5Y CAGR-3.3%

10Y CAGR+0.2%

CME Group paid $5.00 per share in dividends in fiscal year 2025. This represents a decrease of 51.9% from the prior year.

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

64.9%

YoY+0.7pp

5Y CAGR+10.8pp

10Y CAGR+5.1pp

CME Group's operating margin was 64.9% in fiscal year 2025, reflecting core business profitability. This is up 0.7 percentage points from the prior year.

Net Margin

62.5%

YoY+4.9pp

5Y CAGR+19.3pp

10Y CAGR+25.0pp

CME Group's net profit margin was 62.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 4.9 percentage points from the prior year.

Return on Equity

14.2%

YoY+0.9pp

5Y CAGR+6.2pp

10Y CAGR+8.1pp

CME Group's ROE was 14.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 0.9 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$83.5M

YoY-11.2%

5Y CAGR-15.8%

10Y CAGR-3.1%

CME Group invested $83.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 11.2% from the prior year.

CME Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$6.5B+6.4%	$6.1B+9.9%	$5.6B+11.1%	$5.0B+7.0%	$4.7B-4.0%	$4.9B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	$4.2B+7.6%	$3.9B+14.4%	$3.4B+13.9%	$3.0B+14.0%	$2.6B+0.3%	$2.6B
Interest Expense	$173.4M+7.8%	$160.9M+0.9%	$159.4M-2.0%	$162.7M-2.5%	$166.9M+0.4%	$166.2M
Income Tax	$1.3B+23.9%	$1.0B+9.5%	$927.4M+16.0%	$799.3M+8.5%	$736.7M+19.7%	$615.7M
Net Income	$4.1B+15.5%	$3.5B+9.3%	$3.2B+19.9%	$2.7B+2.0%	$2.6B+25.2%	$2.1B
EPS (Diluted)	$11.16+15.4%	$9.67+9.1%	$8.86+19.7%	$7.40+1.5%	$7.29+24.2%	$5.87

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$1.6B+7.2%	$1.5B-9.1%	$1.7B+3.0%	$1.6B+7.7%	$1.5B-3.7%	$1.6B+3.4%	$1.5B+3.0%	$1.5B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	$1.0B+4.8%	$972.6M-13.9%	$1.1B+1.9%	$1.1B+17.0%	$947.1M-7.5%	$1.0B+2.4%	$1.0B+4.3%	$959.6M
Interest Expense	$43.7M-0.7%	$44.0M0.0%	$44.0M+5.5%	$41.7M+2.5%	$40.7M+1.2%	$40.2M+0.2%	$40.1M+0.5%	$39.9M
Income Tax	$395.5M+47.0%	$269.0M-11.9%	$305.2M+5.8%	$288.6M+30.0%	$222.0M-15.9%	$264.1M-2.7%	$271.3M+5.1%	$258.2M
Net Income	$1.2B+30.3%	$908.0M-11.4%	$1.0B+7.2%	$956.2M+9.3%	$874.6M-4.2%	$912.8M+3.4%	$883.2M+3.3%	$855.2M
EPS (Diluted)	N/A	$2.49-11.4%	$2.81+7.3%	$2.62	N/A	$2.50+3.3%	$2.42+3.0%	$2.35

CME Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$198.4B+44.4%	$137.4B+6.0%	$129.7B-25.5%	$174.2B-11.5%	$196.8B+57.9%	$124.7B
Current Assets	$165.4B+60.5%	$103.0B+8.6%	$94.9B-31.8%	$139.1B-14.0%	$161.8B+81.2%	$89.3B
Cash & Equivalents	$4.4B+52.7%	$2.9B-0.7%	$2.9B+7.1%	$2.7B-4.0%	$2.8B+73.6%	$1.6B
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$639.2M+11.5%	$573.1M+7.0%	$535.6M+10.8%	$483.2M+11.2%	$434.5M-5.8%	$461.3M
Goodwill	$10.5B+0.3%	$10.5B-0.1%	$10.5B+0.1%	$10.5B-0.4%	$10.5B-2.5%	$10.8B
Total Liabilities	$169.7B+52.9%	$111.0B+7.8%	$103.0B-30.1%	$147.3B-13.0%	$169.4B+72.3%	$98.3B
Current Liabilities	$160.3B+56.7%	$102.3B+9.5%	$93.4B-32.2%	$137.7B-14.2%	$160.4B+81.9%	$88.2B
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$28.7B+8.5%	$26.5B-0.9%	$26.7B-0.5%	$26.9B-1.9%	$27.4B+4.0%	$26.4B
Retained Earnings	$6.4B+53.7%	$4.2B-6.0%	$4.5B-6.1%	$4.7B-7.9%	$5.2B+3.1%	$5.0B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$198.4B+6.0%	$187.1B+4.0%	$179.9B+14.0%	$157.8B+14.8%	$137.4B-0.3%	$137.8B+11.7%	$123.4B-6.6%	$132.1B
Current Assets	$165.4B+8.2%	$152.8B+5.1%	$145.5B+17.8%	$123.4B+19.8%	$103.0B-0.1%	$103.1B+16.2%	$88.7B-8.8%	$97.3B
Cash & Equivalents	$4.4B+80.5%	$2.4B+23.5%	$2.0B+41.0%	$1.4B-51.4%	$2.9B+24.6%	$2.3B+29.7%	$1.8B+24.6%	$1.4B
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$639.2M-0.6%	$642.9M-3.7%	$667.6M-13.3%	$770.2M+34.4%	$573.1M-8.9%	$629.4M+5.0%	$599.5M-4.6%	$628.2M
Goodwill	$10.5B0.0%	$10.5B-0.1%	$10.5B+0.2%	$10.5B+0.1%	$10.5B-0.3%	$10.5B+0.2%	$10.5B0.0%	$10.5B
Total Liabilities	$169.7B+6.8%	$159.0B+4.5%	$152.2B+16.3%	$130.8B+17.9%	$111.0B+1.3%	$109.6B+14.5%	$95.7B-8.7%	$104.9B
Current Liabilities	$160.3B+7.2%	$149.6B+4.8%	$142.8B+17.6%	$121.4B+18.7%	$102.3B+1.5%	$100.8B+15.9%	$87.0B-9.5%	$96.1B
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$28.7B+1.9%	$28.2B+1.6%	$27.7B+2.6%	$27.0B+2.1%	$26.5B-6.1%	$28.2B+2.1%	$27.6B+1.8%	$27.2B
Retained Earnings	$6.4B+12.7%	$5.7B+8.6%	$5.3B+12.1%	$4.7B+11.9%	$4.2B-28.4%	$5.8B+9.2%	$5.4B+9.5%	$4.9B

CME Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$4.3B+15.9%	$3.7B+6.9%	$3.5B+13.0%	$3.1B+27.2%	$2.4B-11.5%	$2.7B
Capital Expenditures	$83.5M-11.2%	$94.0M+23.0%	$76.4M-14.8%	$89.7M-29.5%	$127.2M-35.6%	$197.5M
Free Cash Flow	$4.2B+16.6%	$3.6B+6.5%	$3.4B+13.9%	$3.0B+30.4%	$2.3B-9.6%	$2.5B
Investing Cash Flow	$1.5B+1914.5%	-$82.6M-495.2%	$20.9M+104.3%	-$489.8M-938.7%	$58.4M+133.3%	-$175.5M
Financing Cash Flow	$56.5B+1013.2%	$5.1B+110.5%	-$48.3B-90.4%	-$25.4B-136.3%	$69.9B+48.0%	$47.2B
Dividends Paid	$3.9B+9.7%	$3.6B+10.8%	$3.2B+22.9%	$2.6B+20.3%	$2.2B+3.8%	$2.1B
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$1.1B+17.1%	$968.1M-8.5%	$1.1B-5.2%	$1.1B+9.7%	$1.0B+1.5%	$1.0B+29.1%	$776.9M-13.0%	$892.7M
Capital Expenditures	$32.5M+76.6%	$18.4M0.0%	$18.4M+29.6%	$14.2M-45.8%	$26.2M-12.1%	$29.8M+63.7%	$18.2M-8.1%	$19.8M
Free Cash Flow	$1.1B+16.0%	$949.7M-8.7%	$1.0B-5.7%	$1.1B+11.2%	$991.7M+1.9%	$973.2M+28.3%	$758.7M-13.1%	$872.9M
Investing Cash Flow	$1.6B+8225.1%	-$19.1M-6.1%	-$18.0M-12.5%	-$16.0M+36.8%	-$25.3M+14.2%	-$29.5M-490.0%	-$5.0M+78.1%	-$22.8M
Financing Cash Flow	$9.9B+54.7%	$6.4B-69.5%	$21.0B+9.3%	$19.2B+2052.2%	-$984.1M-107.4%	$13.3B+244.7%	-$9.2B-576.3%	$1.9B
Dividends Paid	$455.0M-0.1%	$455.3M0.0%	$455.3M-82.3%	$2.6B+513.0%	$418.8M+0.1%	$418.5M0.0%	$418.5M-82.0%	$2.3B
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CME Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	64.9%+0.7pp	64.1%+2.5pp	61.6%+1.5pp	60.1%+3.7pp	56.4%+2.4pp	54.0%
Net Margin	62.5%+4.9pp	57.5%-0.3pp	57.8%+4.2pp	53.6%-2.6pp	56.2%+13.1pp	43.1%
Return on Equity	14.2%+0.9pp	13.3%+1.2pp	12.1%+2.1pp	10.0%+0.4pp	9.6%+1.6pp	8.0%
Return on Assets	2.1%-0.5pp	2.6%+0.1pp	2.5%+0.9pp	1.5%+0.2pp	1.3%-0.3pp	1.7%
Current Ratio	1.03+0.0	1.010.0	1.020.0	1.010.0	1.010.0	1.01
Debt-to-Equity	5.91+1.7	4.19+0.3	3.85-1.6	5.48-0.7	6.18+2.5	3.73
FCF Margin	64.3%+5.6pp	58.7%-1.9pp	60.5%+1.4pp	59.1%+10.6pp	48.5%-3.0pp	51.6%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	61.8%-1.4pp	63.2%-3.5pp	66.7%-0.7pp	67.5%+5.4pp	62.1%-2.5pp	64.6%-0.7pp	65.3%+0.8pp	64.5%
Net Margin	71.8%+12.7pp	59.1%-1.5pp	60.6%+2.4pp	58.2%+0.9pp	57.3%-0.3pp	57.6%-0.0pp	57.6%+0.2pp	57.5%
Return on Equity	4.1%+0.9pp	3.2%-0.5pp	3.7%+0.2pp	3.5%+0.2pp	3.3%+0.1pp	3.2%+0.0pp	3.2%+0.1pp	3.1%
Return on Assets	0.6%+0.1pp	0.5%-0.1pp	0.6%-0.0pp	0.6%-0.0pp	0.6%-0.0pp	0.7%-0.1pp	0.7%+0.1pp	0.7%
Current Ratio	1.03+0.0	1.020.0	1.020.0	1.020.0	1.01-0.0	1.020.0	1.020.0	1.01
Debt-to-Equity	5.91+0.3	5.64+0.2	5.49+0.6	4.84+0.6	4.19+0.3	3.88+0.4	3.46-0.4	3.86
FCF Margin	66.8%+5.0pp	61.8%+0.3pp	61.5%-5.7pp	67.1%+2.1pp	65.0%+3.6pp	61.4%+11.9pp	49.5%-9.2pp	58.7%

Similar Companies

Intercontinental Exchange Inc ICE

$92.6B

Moody'S Corp MCO

$78.5B

Coinbase Global, Inc. COIN

$45.3B

S&P Global SPGI

$128.8B

Nasdaq Inc NDAQ

$49.3B

Frequently Asked Questions

What is CME Group's annual revenue?

CME Group (CME) reported $6.5B in total revenue for fiscal year 2025. This represents a 6.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is CME Group's revenue growing?

CME Group (CME) revenue grew by 6.4% year-over-year, from $6.1B to $6.5B in fiscal year 2025.

Is CME Group profitable?

Yes, CME Group (CME) reported a net income of $4.1B in fiscal year 2025, with a net profit margin of 62.5%.

What is CME Group's EBITDA?

CME Group (CME) had EBITDA of $4.3B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is CME Group's operating margin?

CME Group (CME) had an operating margin of 64.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is CME Group's net profit margin?

CME Group (CME) had a net profit margin of 62.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does CME Group pay dividends?

Yes, CME Group (CME) paid $5.00 per share in dividends during fiscal year 2025.

What is CME Group's return on equity (ROE)?

CME Group (CME) has a return on equity of 14.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is CME Group's free cash flow?

CME Group (CME) generated $4.2B in free cash flow during fiscal year 2025. This represents a 16.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is CME Group's operating cash flow?

CME Group (CME) generated $4.3B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are CME Group's total assets?

CME Group (CME) had $198.4B in total assets as of fiscal year 2025, including both current and long-term assets.

What are CME Group's capital expenditures?

CME Group (CME) invested $83.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

What is CME Group's current ratio?

CME Group (CME) had a current ratio of 1.03 as of fiscal year 2025, which is considered adequate.

What is CME Group's debt-to-equity ratio?

CME Group (CME) had a debt-to-equity ratio of 5.91 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is CME Group's return on assets (ROA)?

CME Group (CME) had a return on assets of 2.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is CME Group's Altman Z-Score?

CME Group (CME) has an Altman Z-Score of 0.57, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is CME Group's Piotroski F-Score?

CME Group (CME) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are CME Group's earnings high quality?

CME Group (CME) has an earnings quality ratio of 1.05x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can CME Group cover its interest payments?

CME Group (CME) has an interest coverage ratio of 24.4x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is CME Group?

CME Group (CME) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.